

# Optimising chlamydia partner therapy in Western Australia

Noëlle Blum, Helen Wood, PhD Candidate, Prof. Rhonda Clifford, PD Dr. Isabelle Arnet and Dr. Sajni Gudka

Pharmaceutical Care Research Group, University of Basel, Switzerland School of Allied Health, University of Western Australia


## Importance of partner therapy<sup>1-4</sup>



- To treat positive partners
- To break cycle of further transmission and re-infection of index
- To decrease the incidence of long-term health implications
- Decrease prevalence

## **Accelerated Partner Therapy (APT)**<sup>5-8</sup>





## Legalities<sup>8,9</sup>



• Legal in UK, US (not all states), Sweden...

• Legal in Victoria, Northern Territory

Western Australia (WA)???


### **Research Questions**



- Barriers and facilitators to
  - Standard partner therapy
  - Accelerated partner therapy
- Investigate potential role of community pharmacist

#### **Methods**





# Results for standard partner therapy<sup>10</sup>



		STANDARD PARTNER THERAPY		
		METRO ONLY	BOTH STUDIES	REGIONAL ONLY
			Sexual partner is not motivated to seek testing	Prescriber doesn't have enough information to contact trace
				Index refuses to name the partner
				Partner has no mobile phone
	Barriers			Partner is part of a mobile community
				Time taken to get diagnosis
				Prescriber not allowed to see partner due to known intimate partner violence
				Other more pressing conditions
				Restrictive work hours
				No dedicated sexual health staff/clinic available in their area
	Facilitators	Able to test for other sites of infection		Service provision without Medicare card
		Able to assess sexual partner		Disguising partner treatment as routine annual screening
		Able to provide education		Living/working in a small community
				Good rapport with the community
				Offering empirical treatment

# Barriers and facilitators to standard partner therapy in regional and remote WA



#### Barriers

- Partner is not motivated to seek testing and treatment
- Prescriber can't contact the partner
- Process barriers in regional and remote: time for test results, more pressing conditions
- Lack of time & staff

"What can be a barrier, is that some of our staff are related to community members. So, then you've got people that don't feel comfortable...they feel like confidentiality is not going to be maintained" Prescriber 1



#### **Facilitators**

- Partner is motivated to seek testing and treatment
- Prescriber's relationship with the community
- Empirical treatment

«Standard partner therapy» does not exist in regional and remote WA!

# »Standard partner therapy» in regional and remote WA



- A. Test and treat on the same day: Prescribers have reported to go directly out into the community with the azithromycin once they had been given a name of a partner
- B. They will give an extra dose of azithromycin to the index for the partner
- C. Prescribers will give a prescription marked with a repeat for azithromycin

"...we just do it in the community. We go to their house with a bottle of water and the azithromycin and make sure they've taken their medication and do contact tracing there too."

Prescriber 2

## Results for accelerated partner therapy



	ACCELERATED PARTNER THE	ERAPY		
	METRO ONLY	BOTH STUDIES	REGIONAL ONLY	
	Prescribing for unseen partner - Lack of opportunity to educate/consult - Empirical treatment	Potential for antibiotic resistance	No local pharmacy	
B. Charles	Lack of remuneration	Inability for further testing /follow up care	Repercussion from doctor's groups	
Barriers	Lack of pharmacy staff	Potential for adverse drug reactions	Lack of time in pharmacy	
	Lack of privacy in a pharmacy		No access to medical history	
	Too accessible		Potential for intimate partner violence	
			Potential for medication tampering	
			Ethical dilemma	
	Provision of chlamydia self-test kits	Discreet prescription annotation	Utilisation of pharmacist to check appropriateness of azithromycin & provide education	
Facilitators	Financial remuneration	Prescriber-led telephone consultation with partner prior to APT	Extra staff	
	Confidential consultation	Pharmacist training		
		Medicare subsidisation/funding		

# Barriers and facilitators to accelerated partner therapy in regional and remote WA



#### **Barriers**

- No local pharmacies
- Repercussions from doctor's groups
- No access to medical history
- Potential for intimate partner violence
- Ethical dilemma

"We don't have a community pharmacy. The closest one is 2-3 hours away" Prescriber 3

#### **Facilitators**

- Pharmacist can check for allergies, provide education

### Pharmacist's role in partner therapy



- Pharmacists are willing to take on a role in partner therapy
- Provide testing, treatment, fill out a pathology request form, educate the partner

#### BUT...

- Self-test kit
- Guidelines
- Restrictions
- Training

### So what?



Various models already in place

Legislation needed

More staff/ dedication to partner therapy

### .....Future research



More research with patients and partners

## **Acknowledgements**



Dr. Lewis Marshall

• Pharmaceutical Care Research Group, University of Basel in Switzerland



#### References



- 1. Kellie Mitchell CG, Byron Minas. The Epidemiology of Notifiable Sexually Transmitted Infections and Blood-Borne Viruses in Western Australia 2016- Appendix. Perth, Western Australia: The Department of Health WA; 2016. Available from: http://ww2.health.wa.gov.au/Articles/A\_E/Epidemiology-of-STIs-and-BBVs-in-Western-Australia
- 2. Shain RN, Perdue ST, Piper JM, Holden AE, Champion JD, Newton ER, et al. Behaviors changed by intervention are associated with reduced STD recurrence: the importance of context in measurement. Sex Transm Dis. 2002 Sep;29(9):520-9.
- 3. James J. Champoux FCN, W. Lawrence Drew, James J. Plorde. Medical Microbiology: An Introduction to Infectious Disases. The McGraw- Hill Companies Inc.; 2004. p. 937.
- 4. Marrazzo J. Clinical manifestations and diagnosis of Chlamydia trachomatis infections. UpToDate; 2018 [updated Jan 17, 2018; cited 2018 22.1]. Available from: <a href="https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chlamydia-trachomatis-infections/print?sectionName=DIAGNOSIS%20OF%20CHLAMYDIAL%20INFECTIONS&anchor=H22688671&source</a>

=see link

- 5. Balfe M, Brugha R, O'Connell E, McGee H, O'Donovan D, Vaughan D. Why don't young women go for Chlamydia testing? A qualitative study employing Goffman's stigma framework. Health, Risk & Society. 2010 2010/04/01;12(2):131-148.
- 6. Rose SB, Smith MC, Lawton BA. "If everyone does it, it's not a big deal." Young people talk about chlamydia testing. N Z Med J. 2008 Apr 4;121(1271):33-42.
- 7. Kissinger P, Hogben M. Expedited Partner Treatment for Sexually Transmitted Infections: An Update. Current Infectious Disease Reports [journal article]. 2011 April 01;13(2):188-195.
- 8. Cameron ST. Patient-delivered partner therapy for chlamydia: a realistic public health measure in the UK. Bjog. 2009 Feb;116(3):345-6.
- 9. Victoria State Government. Patient Delivered Partner Therapy
  Clinical Guidelines. 2015 [cited 2018 9 April]. Available from:
  <a href="https://www2.health.vic.gov.au/about/publications/policiesandguidelines/pdpt-clinical-guidelines">https://www2.health.vic.gov.au/about/publications/policiesandguidelines/pdpt-clinical-guidelines</a>
- 10. Helen Wood CH, Emma loppolo, et al.,. Barriers and facilitators to partner treatment of chlamydia: a qualitative investigation with prescribers and community pharacists: The University of Western Australia 2017.